Why Mark Cuban Is Calling This Signature Trump Healthcare Policy ‘a Win’

Why Mark Cuban Is Calling This Signature Trump Healthcare Policy ‘a Win’

The Cost Plus Drugs co-founder says the administration’s prescription pricing platform is saving patients real money.

BY AMAYA NICHOLE, NEWS WRITER

President Donald Trump and Mark Cuban. Illustration: Inc; Photo: Getty Images

Billionaire entrepreneur Mark Cuban recently shared his feelings on the federal government’s TrumpRx drug platform, saying the initiative will minimize expenses for Americans.

“Everyone wants me to rip on TrumpRx. Reality is, it’s saving patients money on IVF and a few other drugs. A lot of money,” Cuban wrote on X. “IMO, anything that saves patients money is a win.”

In 2022, Cuban co-founded Cost Plus Drugs with the goal of giving Americans access to safe and affordable medicines while also being transparent about the pricing of drugs. President Trump launched TrumpRx last month on similar principles, calling it “the most impactful prescription price reset in the history of our country.”

This isn’t the first time that Cuban has praised the work that TrumpRx is doing. In October, when testifying before a Senate committee about drug pricing and health care modernization, Cuban said of the not-yet-launched program, “We’ll work with TrumpRx. I mean, it’s incredible. It’s stupendous. It’s like the most incredible program ever and so we’re excited to offer them our API so that they’ll be able to download our daily prices so when they go down, everybody benefits.”

How Anthropic's Claude AI Became a Co-Founder

And last month as Cuban promoted his company, he still gave some TrumpRX credit while pointing out the advantages of his own Cost Plus Drugs.

“Of the drugs we both carry, we are cheaper on 90pct. They added a bunch of brands that have generics. So we beat them there. Usually by a lot,” the businessman posted on X.

He continued, adding, “They crushed it on IVF drugs. That’s going to be a lifesaver for a lot of couples. And their efforts to get PBMs out of the picture, was a big step forward as well.”


© Inc.com